Saakshi Khattri

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Emma Guttman‐Yassky, Patrick M. Brunner, Avidan U. Neumann et al. · Journal of the American Academy of Dermatology · 2018 · 338 citations · Full text

Medicine, Dermatology, Immunology +14

The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins

Patrick M. Brunner, Mayte Suárez‐Fariñas, Helen He et al. · Scientific Reports · 2017 · 264 citations · Full text

Medicine, Dermatology, Immunology +17

Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population

Tali Czarnowicki, Juana Gonzalez, Avner Shemer et al. · Journal of Allergy and Clinical Immunology · 2015 · 220 citations · Full text

Medicine, Dermatology, Immunology +16

Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis

Saakshi Khattri, Patrick M. Brunner, Sandra Garcet et al. · Experimental Dermatology · 2016 · 216 citations · Full text

Medicine, Dermatology, Immunology +15

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab

Patrick M. Brunner, Ana B. Pavel, Saakshi Khattri et al. · Journal of Allergy and Clinical Immunology · 2018 · 197 citations · Full text

Medicine, Dermatology, Immunology +14